Hormone Receptor Positive Breast Cancer

ASCO Breast Cancer

ASCO GUIDELINES Apps brought to you free of charge courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/71360

Contents of this Issue

Navigation

Page 4 of 7

Selecting a Treatment Regimen Table 2. Therapies Agent (Brand) Anastrozole (Arimidex® Exemestane (Aromasin® Letrozole (Femara® Tamoxifen (Nolvadex® ) )* * Generic forms available. )* ) Dose 1 mg 25 mg 2.5 mg 20 mg Frequency Once daily Once daily Once daily Once daily Management of Hormone Receptor-Positive Breast Cancer Postmenopausal Pre/Perimenopausal 5 years of tamoxifen 2-3 years of tamoxifen 5 years of tamoxifen Studies are evaluating the role of adding ovarian suppression to tamoxifen for these women. AI 2-3 years AI 3-5 years 3

Articles in this issue

Archives of this issue

view archives of Hormone Receptor Positive Breast Cancer - ASCO Breast Cancer